X

Trial Profile

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Major depressive disorder
Focus Therapeutic Use
Sponsors COMPASS Pathways

Most Recent Events

17 Jul 2023 Primary endpoint (Improvement in depressive symptoms) has been met, according to a COMPASS pathways media release.
17 Jul 2023 Results presented in a COMPASS Pathways Media Release.
17 Jul 2023 According to a COMPASS Pathways Media Release, positive data has been published online in the peer reviewed Nature journal, Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com